cyclophosphamide + non-pegylated liposomal doxorubicin

Cyclophosphamide + non-pegylated liposomal doxorubicin is a combination chemotherapy regimen used primarily in the treatment of breast cancer, including metastatic and recurrent forms. Cyclophosphamide is an alkylating agent that cross-links DNA, leading to inhibition of DNA replication and cell death. Non-pegylated liposomal doxorubicin is an anthracycline antibiotic encapsulated in conventional (non-PEG) liposomes, which intercalates into DNA and inhibits topoisomerase II, resulting in DNA damage and apoptosis. The combination exploits different mechanisms to maximize cytotoxicity against cancer cells at various stages of the cell cycle while aiming to reduce overlapping toxicities compared to free doxorubicin formulations. This regimen has demonstrated efficacy as first-line therapy for metastatic breast cancer with a favorable safety profile[1][2].